Storia della carriera di Michael Cassano
Precedenti posizioni note di Michael Cassano
Società | Posizione | Inizio | Fine |
---|---|---|---|
Orasi Medical, Inc.
Orasi Medical, Inc. Medical/Nursing ServicesHealth Services Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD). | Direttore Tecnico/Scientifico/R&S | 20/04/2009 | 18/08/2012 |
JOHN WILEY & SONS, INC. | Corporate Officer/Principal | - | - |
Formazione di Michael Cassano
University of Minnesota | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 4 |
Posizioni
Chief Tech/Sci/R&D Officer | 1 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Settori
Consumer Services | 3 |
Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
JOHN WILEY & SONS, INC. | Consumer Services |
Aziende private | 1 |
---|---|
Orasi Medical, Inc.
Orasi Medical, Inc. Medical/Nursing ServicesHealth Services Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD). | Health Services |
- Borsa valori
- Insiders
- Michael Cassano
- Esperienza